Convatec appoints Peter Jarvis as Chief Operations Officer

London, UK, 21 April 2026 – Convatec, a leading medical products and technology company focused on chronic condition management, today announced the appointment of Peter Jarvis as Chief Operations Officer, effective 1 June 2026.

Peter joins Convatec with more than three decades of global operational and supply‑chain leadership. He most recently served as Senior Vice President for Supply Chain at Vantive, Baxter’s former Kidney Care business, where he led global supply chain strategy and transformation. Prior to this, Peter spent over 13 years at Baxter International, holding senior roles across Operations, Integrated Supply Chain, Operational Excellence and Supplier Development, including leadership of chronic and acute renal operations in Europe.

Peter also brings significant experience from the automotive sector, having spent more than a decade at General Motors in a series of European supplier‑quality and operational roles, where he led quality and readiness across multiple countries. He began his career in engineering and manufacturing roles in the UK.

In his new role at Convatec, Peter will lead the company’s Global Operations function and manufacturing network around the world, supplying each of Convatec’s care categories. The appointment comes at an exciting time, following Convatec’s recently announced Accelerate strategy, and will strengthen operational performance, enhance customer delivery and support the company’s growth ambitions.

Commenting on the appointment, Jonny Mason, Chief Executive Officer, said: “Peter brings an exceptional track record of operational excellence, quality, growth, transformation and global leadership, drawn from healthcare and beyond. His experience is strongly aligned with our strategy and he will play a key role on our executive team as we continue to accelerate in 2026 and beyond.”

On his appointment, Peter Jarvis said: “Convatec’s vision and forever caring promise are really important to me. They reflect a genuine commitment to people living with chronic conditions. The progress the company has made in recent years is impressive, and the ambition for the future is inspiring. I’m delighted to be joining such a purpose‑led, performance-driven team and look forward to contributing to Convatec’s continued success.”

Contact

Media: MediaRelations@convatec.com

Investor relations: ir@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com.